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Background:	An unintended consequence of CF newborn screening (NBS) is the identification of infants with a positive NBS test, but indeterminate diagnostic test.  These infants are classified as CF screen positive/indeterminate diagnosis (CFSPID) in Europe and CFTR related metabolic syndrome (CRMS) in the USA.  CRMS/CFSPID infants present a diagnostic challenge to CF clinicians and a stress on families of these infants.  As CF NBS has become more widespread across the world, increased information about the epidemiology and outcomes of these infants has become available.  

Methods: At the CF Foundation Consensus Conference, participants reviewed the most recent studies of CRMS/CFSPID and worked to develop a harmonized definition of CRMS/CFSPID.  

Results:  Several studies of CRMS/CFSPID from populations around the world have been published in the past year.  Although the studies vary in the number of infants studied, study design, and outcome measures, there have been some consistent findings.  CRMS/CFSPID occurs relatively frequently, with a CF:CRMS case ratio that ranges from 3-5 CF cases for every 1 CRMS/CFSPID case.  The majority of CRMS/CFSPID do not develop CF disease or convert to a diagnosis of CF.  However, between 10-20% of infants can develop clinical features concerning for CF, such as a respiratory culture positive for Pseudomonas aeruginosa.  Most all the studies have only reported short term outcomes in the first 1-3 years of life; the long term outcomes of CRMS/CFSPID remain unknown.  The ECFS definition of CFSPID and the CFF definition of CRMS differ only slightly, and the Consensus Conference was able to create a unified definition of CRMS/CFSPID.  





During the development of the 2008 cystic fibrosis (CF) diagnosis consensus guidelines, it was recognized that the increased implementation of newborn screening (NBS) had led to a new and complex diagnostic dilemma of infants with abnormal NBS tests but inconclusive sweat tests and/or DNA test results  ADDIN EN.CITE [1].  Different CFTR mutations can result in different levels of protein or function, with varying phenotypic effects -- from an absence of disease symptoms for many years at one end of the spectrum, to severe, life-shortening lung disease at the other end.  An unequivocal normal result or a CF diagnosis, confirmed by a clearly normal or abnormal sweat chloride concentration, can be achieved for most patients following a positive CF NBS test, but in some infants with a positive CF NBS test there may be insufficient genetic or sweat test data to make the diagnosis of CF.  Rather than attempting to manage this complex situation in the 2008 diagnostic guidelines, a separate CF Foundation consensus conference was convened to address the issue.  An expert panel, using the Delphi method [2], created a new diagnostic term, CFTR-Related Metabolic Syndrome (CRMS), and recommendations for management  ADDIN EN.CITE [3].  CRMS is the term used in the United States to describe infants with elevated immunoreactive trypsinogen (IRT) levels, but with insufficient sweat chloride or genetic data to make the diagnosis of CF.  Although this condition is not a metabolic disorder, the designation metabolic syndrome was established in part to have an International Classification of Diseases medical code for US healthcare delivery system follow-up and billing purposes.  However, the term CRMS has not been accepted in Europe and some other countries due to concern about its appropriateness and a feeling that it was difficult for families to understand.  Thus, a similar term, CFSPID, for CF Screen Positive, Inconclusive Diagnosis  ADDIN EN.CITE [4], was developed in a Delphi process by the European Cystic Fibrosis Society (ECFS) Neonatal Screening Working Group and introduced recently in Europe as an alternative to CRMS.  

Both CRMS and CFSPID are diagnoses that, as with every diagnosis, should stimulate a clinical management plan.  Indeed, each of the original consensus articles describing CRMS and CFSPID included action plans for follow-up care  ADDIN EN.CITE [3,4].  In addition, the CF Foundation organized a third consensus conference to focus on developing comprehensive care guidelines for infants diagnosed through NBS that extend to 2 years of age.[5]  Thus, the CF Foundation recommendations in current use arose from three essentially concurrent consensus exercises published in 2008-09, to be applied as an integrated “package.” ADDIN EN.CITE [1,3,5]  The ECFS recommendations following recognition of a CFSPID designation, however, embrace the philosophy of CFSPID as a staging post, requiring further steps for management, but not necessarily reflective of any pathology.  

The planning committee for the 2015 Diagnosis Consensus Conference recognized that with the increasing use of CF NBS worldwide, CRMS and CFSPID have become important aspects of the CF diagnostic process.  Therefore, there conference included as session to review recent published and unpublished data on CRMS and CFSPID populations.  An important goal of the conference was to develop a consensus unified definition of CRMS and CFSPID which could allow for collection of data from populations around the world and increase our understanding of the epidemiology and outcomes of CRMS/CFSPID.  At the conclusion of the conference, consensus recommendations were crafted and agreed upon by electronic survey (Table 1).

Harmonization of US and ECFS Terminology
CRMS.  In the United States, the expert consensus panel specifically created a term that did not imply the infant has CF, while still acknowledging that these infants required follow up by CF specialists. ADDIN EN.CITE [3]  CRMS (ICD-10 code E88.89) was defined as an infant who is asymptomatic and hypertrypsinogenemic, and who has either: 
	Persistently intermediate sweat chloride levels (30-59 mmol/L if age <6 months or 40-59 mmol/L if age ≥ 6 months) and fewer than 2 CF-causing CFTR mutations OR
	A sweat chloride concentration <30 mmol/L and 2 CFTR mutations with 0 to 1 known to be CF-causing

CFSPID.  In Europe and some other countries, especially when international coding is not required for healthcare delivery, expert consensus differed slightly on how to define this group.  In the initial ECFS consensus process  ADDIN EN.CITE [4], it was recommended that these infants should not have a designation, but in the second exercise,[13] five years later, it was clear that the majority of respondents felt a designation was needed.  In the subsequent voting exercise (including CRMS as an option), there were two clear favorites:  CF Inconclusive Diagnosis (CFID) and CF Screen Positive, Equivocal Diagnosis (CFSPED).  An expert panel decided to amalgamate the two terms, and CF Screen Positive, Inconclusive Diagnosis (CFSPID) reached high levels of agreement in the subsequent round of the Delphi exercise, creating a category for infants who are asymptomatic and hypertrypsinogenemic  ADDIN EN.CITE [4], and have either: 
	0 or 1 CFTR mutations, plus intermediate sweat chloride (30-60 mmol/L), OR 
	2 CFTR mutations, at least 1 of which has unclear phenotypic consequences, plus a normal sweat chloride (<30 mmol/L)

The ECFS expert panel felt that by grouping these infants under the term CFSPID and avoiding any terms that suggest disease (such as CRMS), they would be more likely to avoid unnecessary medicalization.

Risks and Benefits of Labels.  There are risks to labeling infants with CRMS and even with CFSPID, including anxiety in parents and families, and increased health-care costs due to extensive and potentially expensive diagnostic evaluations.  Currently, there are widely different practices regarding the depth, frequency, and duration of these evaluations with no consensus on best practice.  A detailed work-up, including DNA sequencing and ancillary tests could resolve the diagnosis of CF, but there can also be cases that continue to remain inconclusive, despite extensive testing.

Overall, however, creation of a category for these infants is beneficial because it allows these NBS-positive patients who cannot be clearly diagnosed with CF but remain at risk of CF to be followed so that treatment, if needed, can be initiated quickly for optimal outcomes.  It also allows for epidemiologic studies to be performed that will help define the disease risk and outcomes for this group of individuals.  

The differences between the definitions of CRMS and CFSPID are so minor as to be clinically insignificant.  The CF Foundation recognizes that “CFSPID” is a helpful term that should be used in describing this complex situation to parents and families.  However, the term “CRMS” will continue to be required for entry of this group of individuals into the US health care system, as well as their continued management.  Recognizing that the two groups are, in fact, one, will allow collection of data from all these individuals, and improve our understanding of this population.  The following unified definition was proposed and approved by the committee by electronic survey:  

Harmonized Definition of CRMS/CFSPID: Infants will be designated as CRMS/CFSPID if they present a positive CF NBS test plus:
	Sweat chloride < 30 mmol/L and 2 CFTR mutations with 0-1 CF-causing CFTR mutations, OR
	Sweat chloride 30-59 mmol/L and < 2 CF-causing CFTR mutations
CFTR mutations that have been shown to be non-CF-causing should not be considered when applying the definition.  Also, note that CRMS/CFSPID infants with sweat chloride levels of 30-59 mmol/L may have 0, 1, or 2 CFTR mutations, as long as they do not have 2 CF-causing mutations.  

To provide additional guidance, the consensus conference also reviewed recent data from the European Union, Australia, and the United States on frequency of occurrence and outcomes of infants categorized as CRMS or CFSPID.  These studies were used to generate recommendations for further testing in CRMS/CFSPID, including genetic and ancillary studies that may help diagnose CF or identify infants likely to develop clinical features of CF (Table 1).  

Prevalence, Clinical Features, and Outcomes of CRMS/CFSPID 
Overview: Nutritional indices in this population are generally good.  An analysis of data on infants with CRMS reported from 2010-2012 to the US CF Foundation Patient Registry (CFFPR) showed that almost all the CRMS infants in the CFFPR were pancreatic sufficient,[11] consistent with other recent studies of CRMS.  However, a higher than expected rate of respiratory cultures may be positive for bacteria typically associated with CF ADDIN EN.CITE [6-9]; for example, in the CFFPR study, 11% of the infants in the CRMS group had at least 1 positive P. aeruginosa respiratory culture during the first year of life, a proportion higher than that reported in the non-CF population,[11] underlining the need for these infants to be followed.  While it is important to ensure that these infants are monitored, they must not be diagnosed with CF erroneously, causing increased health care costs and inappropriate levels of anxiety in the families.  Thus, the follow-up requires a careful balance between surveillance and readiness to diagnose with CF and treat.  Several recent longitudinal observational studies (Table 2) have provided information about CRMS/CFSPID outcomes and show that these infants do have a small risk of developing CF over time.  The results of these studies, described briefly below, can help provide guidance on determining how this vulnerable group should best be monitored.   

CRMS in Wisconsin.  The relation between CRMS and a CF diagnosis was studied in Wisconsin in a total of 376 CF NBS-positive infants. ADDIN EN.CITE [6]  These patients were divided into 3 groups:  CF, CRMS, and CFTR-related disorder (CFTR-RD).  The infants in the CFTR-RD category represented 5% (19/376) of the studied cohort compared with 15% (57/376) in the CRMS group.  The median IRT value of the CFTR-RD group was 106 ng/mL (range 64-161), whereas that of the CRMS group was 94 ng/mL (range 47-262); sweat chloride concentration was 43 mmol/L in CFTR-RD and 35 mmol/L in CRMS.  Both groups were all pancreatic sufficient and both included p.Arg117His (7T) mutations, as well as 5T-12TG variants.  Infection frequencies with P. aeruginosa were similar, at 32% (CFTR-RD) and 39% (CRMS).  The CFTR-RD group, however, represented a higher degree of disease severity than did the CRMS group.  

CRMS in California.  The large, diverse California population provides additional insight into the CRMS population.[10]  The California CF NBS algorithm utilizes a 40-mutation genetic screen, specific to their population, in all high-IRT infants.  Infants with 2 mutations are screen-positive.  Infants with only 1 California-panel mutation identified undergo gene scanning and sequencing, and only those with 1 or more additional CFTR mutations are considered to have a positive newborn screen.  From 2007-2012, there were 1,012 positive CF NBS results among 2.5 million newborns tested.  Of those, 345 were diagnosed with CF (20 of whom were initially considered CRMS); 553 were categorized as CRMS (including the 20 who were later given a CF diagnosis), and 1617 were designated healthy carriers.  In addition, 28 infants were later diagnosed with CF following false-negative NBS results.  Thus, in California, there was a rate of approximately 3 CRMS infants for every 2 infants diagnosed with CF.  (While the data from the California NBS program are illuminating, neither the consensus committee nor the Clinical and Laboratory Standards Institute recommends the use of this algorithm for CF diagnosis.)

It is likely that the gene sequencing required by the California program is at least partially the cause of the identification of large numbers of infants categorized as CRMS, and it is useful to examine whether this results in an overall benefit.  Some of the infants are labelled as CRMS due to the presence of novel CFTR mutations whose disease-causing potential is unclear.  Over the first 3 years of the California NBS program, 55 novel CFTR variants were identified in the 524 infants with 2 mutations detected. ADDIN EN.CITE [11]  Of the 424 infants with adequate follow-up, novel CFTR variants were detected about equally in the group of infants diagnosed with CF (14/110, 12.7%) during the 3-year study compared to those who stayed in the CRMS group (28/279, 10%). Thus, in this population, the detection of novel CFTR variants resulted in the identification of 14 additional children with CF at the “cost” of adding another 28 children to the CRMS category who may or may not eventually become symptomatic.  Further analysis of these infants has shown that infants with a non-CF causing CFTR mutation have benign outcomes, but that those with mutations of varying clinical consequences can potentially develop CF. ADDIN EN.CITE [12,13]  

The California algorithm for a CF diagnosis following a positive CF NBS result requires at least one of the following: 
	The presence of 2 CF-causing mutations in trans, OR
	Sweat chloride levels ≥ 60mmol/L, OR
	Fecal elastase ≤ 200μg/g, OR
	Meconium ileus in the neonatal period, OR
	Sibling with the same genotype and established CF diagnosis, OR
	Compatible clinical features per CF physician
In the first five years of the California NBS program, conversion from CRMS to a CF diagnosis due to clinical presentation was not uncommon:  6.4% (n=24) of all final diagnoses of CF resolved due to one or more clinical symptoms, including failure to thrive/gastrointestinal involvement, respiratory involvement, or P. aeruginosa infection (n=7; 29%).  Two of the 24 patients (8%) eventually displayed diagnostic sweat chloride levels.[10]  

CRMS in US CF Foundation Patient Registry.  The US CF Foundation Patient Registry (CFFPR) collects data from all the accredited CF care centers in the United States.  In 2010, CRMS was added as a diagnostic category, and Ren, et al reported the outcomes in CRMS infants from 2010-2012. ADDIN EN.CITE [9]  A total of 1,540 infants met the diagnostic criteria for a CF diagnosis in that timeframe, and 309 met the criteria for CRMS (a ratio of 5.0:1.0).  

Variations in diagnostic criteria and terminology have a significant impact on the quality of data in CF registries.  Moreover, attempts to compare registry-based outcome data from different regions and countries have been fraught with difficulties, limiting research opportunities.[14]  A prime example of this can be found in the wide disparity of CRMS cases reported in various regions.  In New York, for example, the reported incidence of CRMS is approximately one-third the incidence of CF (251 CF:94 CRMS), ADDIN EN.CITE [8] whereas the reported incidence of CRMS in California is approximately 1½ times the incidence of CF (373 CF:533 CRMS).[10]  This may be due both to differences in screening protocols [15] and to divergent state demographics.  In the CFFPR, only 6.5% of individuals with CF self-declare as non-White and 12.5% as Hispanic; in the CRMS group, 11.7% are non-White and 19.1% are Hispanic.[16]  The relatively higher proportion of Hispanic infants in the CRMS group, however, could be due to the large numbers of infants reported with CRMS from California, which has a large Hispanic population and which uses an NBS algorithm with a greater probability of CRMS detection.  The CFFPR also reports a higher proportion of African-American (AA) infants in the CRMS group, but that could reflect the fact that AA infants tend to have higher IRT levels,[17] while CF itself is less common in the AA population, leading to a higher number of false-positive NBS tests.  

Both the New York and California CRMS rates diverge widely from national data, which suggest a much lower incidence of CRMS.[11]  Of the 1,983 infants entered into the Registry from 2010-2012, 1,540 met the diagnostic criteria for CF and 309 infants met the criteria for CRMS; that is, CRMS was reported at one-fifth the incidence of CF.  However, 40.8% of infants that fit a CRMS definition were actually registered as CF by the recording CF center.  In addition, 8 of those infants placed into the CRMS category should actually have been diagnosed with CF.  The problem is widespread:  13 states in 2010-2012 entered a CF diagnosis inappropriately for at least 10% of their infants in the CFFPR. ADDIN EN.CITE [9]  It may be possible that clinical data not entered into the Registry affected the decision to classify an infant as CF.  However, it is also possible that there is some confusion or disagreement with consensus guidelines.  A more consistent approach to classification is important in order to reduce variations in CRMS/CFSPID incidence that can have a significant impact on registry data quality and epidemiology research efforts.  

CFSPID in Australia.  In New South Wales, Australia, infants are categorized as CFSPID if they have a high IRT on NBS, one copy of p.Phe508del, and sweat chloride concentration of 30-59 mmol/L.  A retrospective long-term follow-up of 29 infants in this group revealed approximately half (n=14) were eventually diagnosed with CF and referred to as “delayed-CF,” although the course of CF was milder compared with NBS-positive CF cases.[18]  From this study, the estimated risk of a future CF diagnosis is 48%, much higher than that found elsewhere in the literature (8-15%, see below).  However, many of the infants were diagnosed as “delayed-CF” based on nonspecific respiratory symptoms, such as cough.  

At the consensus conference, investigators from Victoria, Australia presented their experience involving 111 infants with positive NBS results (high IRT, one CFTR mutation) and sweat chloride concentration of 30-59 mmol/L.  The clinical practice at that time was to perform clinical assessment at 4-6 weeks of age, fecal elastase measurement, and extended CFTR mutation analysis.  The infants were seen again at 6-12 months of age and sweat testing was repeated.  Infants with sweat chloride concentration <40 mmol/L, only 1 CFTR mutation found, and no clinical features of CF were considered carriers and referred for genetic counseling only.  Infants with clinical features of CF or with a diagnostic sweat chloride concentration (≥ 60 mmol/L) or in whom a second CF-causing mutation was found were referred for CF care.  Individuals who continued to display sweat chloride concentration 30-59 mmol/L, or found to have a second CFTR mutation of unknown significance or indeterminate clinical features, were not considered to have CF and were referred for annual clinical assessment, with a repeated sweat test ordered when they reached 5 years of age.  Over the 20-year study period, 15 children received a diagnosis of CF and 96 were determined to be healthy carriers.  In the group of individuals with intermediate sweat chloride concentrations, the higher the value, the more likely the individual would eventually receive a CF diagnosis (Table 3).  The Victoria experience showed that the vast majority of these children never received a CF diagnosis, but a small minority did.   

CFSPID in Canada and Italy.  A joint study was conducted in Canada and Italy comparing health outcomes of 82 individuals categorized as CFSPID with the health outcomes of 80 matched individuals with CF diagnosed through NBS. ADDIN EN.CITE [7]  CFTR mutation rates did not differ between the CF and CFSPID groups; extensive gene analysis showed that 2 CFTR mutations were present in 96.3% of individuals in the CFSPID group, compared with 92.5% in the CF group.  P. aeruginosa and S. aureus were isolated in 12% and 40%, respectively, of subjects with CFSPID, although that was significantly less than in patients with CF (31% P. aeruginosa and 71% S. aureus).  In the CFSPID group, there was a slight increase in sweat chloride concentration throughout the first 2-3 years of life, and in 9 of the 82 children in the CFSPID group (11%), CF was eventually diagnosed through abnormal sweat chloride results, reclassification of their CFTR mutations as CF-causing, or a combination.  Infants that converted from the CFSPID category to a CF diagnosis had significantly higher serial sweat chloride levels (P< .0001) and serum trypsinogen (P = .009) levels than did individuals who remained in the CFSPID group.  

 CFSPID in United Kingdom. (To be completed)
Data were collected on a similar population in the UK.  Some confusion between the UK and other European data occurs, especially regarding those infants with 2 CFTR mutations and sweat levels of 30-59 mmol/L, because the ECFS considers that to be indicative of CF, whereas the UK does not.  An additional area of confusion occurs with those children who have the same CFTR gene mutations as a sibling followed as CFSPID, but did not present with a positive newborn screen. In summary, four prospective studies and 1 retrospective study have been carried out in the UK on individuals who do not meet CF diagnostic guidelines following NBS but are at increased risk for CF according to US or ECFS guidelines.  

Recommendations for Follow-Up of Infants Labeled CRMS/CFSPID
Following a review of data presented at the consensus conference, recommendations for follow-up were agreed upon by electronic survey of the consensus committee (Table 1).  The committee determined that when an infant is labeled CRMS/CFSPID (by the harmonized definition described above), a clear explanation must be given to the parents and primary care provider (PCP).  Genetic counselling should be offered to the family.  The children should undergo at least one repeat sweat chloride test at the CF center, and extended CFTR genetic analysis, as well as CFTR functional analysis, can be considered.  Parents and the PCP should understand that children labeled as CRMS/CFSPID must be followed at a specialized CF care center (see Case Studies) because some will develop symptoms, although which individuals will progress to develop symptoms cannot be predicted at the level of the individual.  





In the past few years, several studies of CRMS and CFSPID have been reported from across the world.  Although they vary in terms of patient characteristics, sample size, and study design, some common themes have emerged.  CRMS/CFSPID is a relatively common outcome of CF NBS, and CF clinicians and PCPs must be prepared to counsel families with these infants.  The majority of CRMS or CFSPID infants do not go on to convert to a CF diagnosis, but  in some infants, the diagnosis of CF is eventually made through an increase in the sweat chloride concentration into the CF diagnostic range, or through reclassification of an infant’s CFTR mutation as disease-causing based on increased knowledge of CFTR genetics. Additionally, infants may be diagnosed subsequent to the development of clinical features concerning for CF, such as a positive respiratory culture for P. aeruginosa.  

Although the short-term outcomes associated with CRMS/CFSPID are benign, we still lack long-term outcome data.  Studies of large cohorts of CRMS/CFSPID infants are essential in order to better understand the relationship between CRMS/CFSPID and CF and CFTR-RD and provide more information to CF caregivers to counsel families of these infants.  A harmonized definition will facilitate research into the frequency and clinical outcomes of these infants, which should address a number of concerns:  
	Will these patients remain free of severe symptoms, or will they demonstrate increasing pathology, just “phase shifted” a few decades?
	Are current recommendations for management, including testing and follow-up, optimal? 
	Can the CF care team be proactive in protecting these individuals from CF pathology or should they only be reactive?  
	What is the financial and psychological impact of following a child who appears to be healthy/normal?  
	When can we release an individual from a designation of CRMS/CFSPID?  Even if they are asymptomatic as infants and children, will some of them eventually present as CFTR-RD?  
These important questions need answers if we are to monitor this group of children optimally.  However, this consensus conference focused on diagnosis and definitions, not management.   Thus, while the definitions of CRMS and CFSPID should be harmonized as described above, no recommendations on were made, and the management of these infants in Europe and other countries could differ from that in the United States.  CF Foundation guidelines for the management of CRMS infants were published in 2009, and it is likely that they will be revised in the near future to reflect the additional knowledge gained since that time.  
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Case Study #1:  High IRT + p.Phe508del + intermediate sweat test result
Parents of Infant Luck are notified that he has screened positive for IRT and one copy of p.Phe508del by CF NBS performed by their state department of health. Their pediatrician recommends that the child wait until 10 days of age and then obtain a sweat test at an accredited CF care center. At two weeks of age, the test is completed and the result is 31mmol/L. The child is now 12 ounces over birth weight and without respiratory symptoms. 
What is true about Infant Luck at this time?
1)	His normal exam and history, NBS result and sweat test are consistent with CRMS/CFSPID
2)	He should be considered for extended CFTR gene analysis 
3)	He should undergo at least one repeat sweat test
4)	All of the above

The definition of CRMS/CFSPID applies to an infant positive for CF NBS, one or no CF causing mutations and an intermediate sweat test such as infant Luck. He should be referred to a CF center for evaluation, further testing and education.

********************************************************************************************************************************************
Case Study #2:  High IRT and p.Phe508del/p.Arg117His 
Infant Manning is a one-week-old female presenting to the pediatrician for a first visit following an uneventful pregnancy and normal vaginal delivery.  She has been steadily improving in her breastfeeding time and is currently at her birth weight after being several ounces down at the time of discharge from the hospital.  The only parental concern is some nasal stuffiness and occasional sneezing. Her examination is within normal limits.
She was born in a state that utilizes IRT/DNA for NBS and was positive for 2 mutations.  These were identified as p.Arg117His and p.Phe508del. The polyT intron analysis revealed 7T/7T. 





What is the next appropriate step that should be taken by the pediatrician?
a)	Referral to CF center for evaluation and sweat chloride testing.
b)	Observe for first year of life and refer to CF center if clinical symptoms suggestive of CF develop.
c)	Send for detailed genetic analysis of the CF gene.
d)	Send for sweat testing at accredited lab and observe for first year of life with referral to CF center if symptoms develop.
The diagnosis of CRMS/CFSPID is given after a positive newborn screen and either: a sweat test value < 30 mmol/L and 2 CFTR mutations, at least one of which has unclear phenotypic consequences OR an intermediate sweat chloride value (30-59 mmol/L) and one or no CF causing mutations. In this infant, the p.Arg117His with 7T is the mutation that is unclear in its clinical significance but in a few patients has been associated with the development of symptoms consistent with CF. Referral to a CF center for evaluation and education is warranted. The term CRMS/CFSPID is reserved for those screen-positive infants without clinical features consistent with CF. Following consensus guidelines from 2008 would have resulted in considering this infant not to have CF, and would direct no follow-up. This is a significant shift in guidance. 

********************************************************************************************************************************
Case Study #3:  California NBS testing for mutations that are not CF-causing
Jake is a 2-week-old infant born in California at 39 weeks gestation following a normal pregnancy and perinatal period. He presented to his pediatrician for the 2-week visit. His mother had received a call the previous day to inform her that Jake had tested positive for CF and that she would hear from the local CF center soon to schedule an appointment to go over the results. According to the California CF NBS protocol, Jake’s initial IRT was elevated at 75 ng/mL and the subsequent DNA testing panel revealed a single mutation p.Gly551Asp. Jake’s DNA was subjected to sequencing, revealing a second mutation, and a positive screen test was reported. Jake’s final mutations included p.Gly551Asp and c.958T>G (p.Leu320Val). 
At the CF center visit, Jake was asymptomatic. He had surpassed his birth weight and was taking a 20 kcal/oz formula. What is the next step recommended for Jake’s pediatrician to take in evaluating the California state positive NBS test?
a)	Offer routine well child checks and see him at 1 month of age
b)	Repeat genetic analysis for the CF gene
c)	Refer to an accredited CF care center lab for sweat chloride testing
d)	Offer counseling and observe for any symptoms without any further diagnostic work up






What is the next appropriate step to take?
a)	Refer for genetic counseling.  Educate the family and pediatrician to recognize any signs of CFTR-related manifestations.
b)	Refer back to the CF center for repeat sweat testing
c)	Repeat detailed genetic analysis for the CF gene
d)	Chest radiograph and sputum culture





Case Study #4: Use of NPD/ICM to facilitate diagnosis when sweat chloride is equivocal

Infant Ines was referred at 3 weeks of age for elevated IRT; only one mutation p.Arg334Trp was found on the limited NBS genetic panel. Sweat test was in the indeterminate range at 40 mmol/L. The repeat test obtained three weeks later was again indeterminate at 34 mmol/L. On physical examination, she was growing well and her examination was within normal limits. A review of the CFTR2 database indicated that p.Arg334Trp causes CF when combined with another CF-causing mutation. The parents were concerned and wanted to know your diagnosis for their infant.







Sweat test was repeated at 6 months of life and remained in the intermediate level at 48 mmol/L. Overall, she had been clinically stable. What is the next appropriate step for diagnosis?
a)	Local follow-up and send to the CF referral center if abnormal symptoms
b)	Referral to a validated CF center lab that has the capability to perform nasal potential difference (NPD) or intestinal current measurement (ICM) and expanded genetic analysis
c)	Referral to a genetic counselor
d)	Initiation of CF specific therapies

The patient was evaluated at the CF center. Fecal elastase of the stool was normal at 550 µg/g. The baby did not have any respiratory symptoms. Detailed genetic analysis was initiated. The infant was referred for evaluation of CFTR function based on ICM on rectal biopsy. Results demonstrated a reduction of CFTR-dependent chloride transport, suggesting the presence of a second mutation associated with residual CFTR activity. 





Table 1.	Summary consensus statements related to CRMS/CFSPID
For infants with CRMS and those designated as having a condition known as Cystic Fibrosis Screen Positive, Inconclusive Diagnosis (CFSPID):
The term CRMS is used in U.S. for health care delivery purposes32 (​file:​/​​/​​/​C:​/​Users​/​pmf700​/​Desktop​/​Approved%20Dx%20consensus%20statements%20for%20CFF%20CC%2004.27.16.doc#_ENREF_32​) and CFSPID43 (​file:​/​​/​​/​C:​/​Users​/​pmf700​/​Desktop​/​Approved%20Dx%20consensus%20statements%20for%20CFF%20CC%2004.27.16.doc#_ENREF_43​) is used in other countries, but these both describe an inconclusive diagnosis following NBS. 
The term CFSPID/CRMS is reserved for screen- positive individuals without clinical features consistent with a diagnosis of CF.
The definition of CFSPID/CRMS is:An infant with a positive NBS test for CF ANDEITHER A sweat chloride value less than 30 mmol/L and two CFTR mutations, at least one of which has unclear phenotypic consequencesOR An intermediate sweat chloride value (30-59 mmol/L) and one or no CF causing mutations
Children designated as CFSPID/CRMS should undergo at least one repeat sweat chloride test at CF centers with suitable expertise, such as an accredited CF center.
Children designated as CFSPID/CRMS should have clinical evaluation performed by CF providers to identify the minority that may develop clinical symptoms.
Children designated as CFSPID/CRMS can be considered for extended CFTR gene analysis (sequencing and or deletion duplication testing), as well as CFTR functional analysis (NPD/ICM) testing to further define their likelihood of developing CF.
The decision to reclassify children designated as CFSPID/CRMS as CF is an integrated decision that should take into account functional assessment of CFTR (sweat chloride, and possibly NPD/ICM), CFTR genetic analysis, and clinical assessment by the CF clinicians caring for the patient.
Genetic counseling should be offered to families of individuals followed for CFSPID/CRMS, including a discussion of the risk in future pregnancies.




Table 2. Summary of Recent Studies of CRMS/CFSPID.
	Groves, et a ADDIN EN.CITE [19]l	Levy, et a ADDIN EN.CITE [6]l	Kharrazi, et al[10]	Ooi, et al ADDIN EN.CITE [7]	Ren, et al ADDIN EN.CITE [9]
Study Design	Retrospective Case Control	Prospective Cross-sectional 	Prospective Cohort	Prospective Case Control	Prospective Cohort
Location	Australia	Wisconsin, USA	California, USA	Multi-national	USA






Increased Sweat Chloride ≥60 mmol/L	4 (14%)	Initial <30, n=14 (27%)Initial 31-59,     n=38 (73%)	22 (3.2%)	3 (33%)	N/A
P. aeruginosa %	78.6	39%	N/A	14.6	10.7
S. maltophilia %	N/A		N/A	4.9	9.4
Pancreatic insufficiency	4 (13.8%)	0	3 	0	14 (4.5%)
p.Phe508del/p.Arg117His	4 (28.5%)	36/57(63%)◊	N/A	19.5%	26.1%
+28% Lost to follow up
*Diagnosed as CF through reclassification of a second disease-causing mutation or increased sweat Cl-
**Number of CF infants inferred based on reported annual rate of new diagnoses and timespan of study.  
***CRMS definition was different from CRMS/CFSPID
†Diagnosed through clinical signs and symptoms of respiratory disease or PI.  Eight were diagnosed through respiratory symptoms





Table 3. Conversion from CRMS/CFSPID to CF by initial sweat chloride concentration in infants with a positive NBS in Victoria, Australia.  
 
Sweat chloride (mmol/L)	Number	CF (%)
30-39	69	3 (4.3%)
40-49	33	7 (21.2%)
50-59	9	5 (55.6%)
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